scholarly journals ASCO virtual meeting 2020: highlights head and neck cancer

2021 ◽  
Author(s):  
Thorsten Fuereder
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Open Questions ◽  
Cancer Field ◽  
Virtual Meeting ◽  
Metastatic Setting ◽  
Risk Patients

SummaryAt the ASCO 2020 virtual meeting, multiple clinically relevant studies were presented addressing open questions in the head and neck cancer field: Are de-escalation strategies feasible in low risk patients? What is the appropriate platinum dose in combination with radiotherapy in high-risk patients suffering from locally advanced disease? Is immunotherapy the first line standard of care for all patient in the recurrent/metastatic setting? This article summarizes the most significant head and neck cancer studies presented at the ASCO 2020 virtual meeting and discusses the data in the context of the current literature.

Induction Chemotherapy in Locally Advanced Head and Neck Cancer: A New Standard of Care?

2008 ◽  
Vol 22 (6) ◽  
pp. 1155-1163 ◽  
Author(s):  
Jochen H. Lorch ◽  
Marshall R. Posner ◽  
Lori J. Wirth ◽  
Robert I. Haddad
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Induction Chemotherapy ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Advanced Head

scholarly journals Special Issue about Head and Neck Cancers: HPV Positive Cancers

2020 ◽  
Vol 21 (9) ◽  
pp. 3388 ◽  
Author(s):  
Panagiota Economopoulou ◽  
Ioannis Kotsantis ◽  
Amanda Psyrri
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Economic Status ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Papilloma Virus ◽  
High Risk Sexual Behavior ◽  
Hpv Status ◽  
Delays In Diagnosis

The oropharynx has become the leading primary site for Human Papilloma Virus (HPV)-associated head and neck cancer. HPV positive oropharyngeal squamous cell carcinoma (HPV+ OSCC) has emerged as an epidemic not easily recognized by many physicians, resulting in delays in diagnosis and management. HPV+ OSCC traditionally refers to younger, healthier patients with high economic status and high-risk sexual behavior and is related to improved prognosis. De-intensification strategies are being evaluated in ongoing clinical trials and if validated, might help spare severe morbidity associated with current cisplatin-based chemoradiotherapy, which is the standard of care for all patients with locally advanced head and neck cancer. On the other hand, whether HPV status represents an important prognostic factor for non-oropharyngeal sites remains to be elucidated.

scholarly journals ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

2021 ◽  
Author(s):  
Thorsten Fuereder
Keyword(s):  
Head And Neck Cancer ◽  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Standard Of Care ◽  
Treatment Intensification ◽  
First Line ◽  
Open Questions ◽  
Virtual Meeting ◽  
Metastatic Setting ◽  
Line Standard

SummaryDuring the ASCO 2021 virtual meeting, multiple clinically relevant studies were presented addressing open questions regarding the therapy of nasopharyngeal carcinomas (NPC): Is immunotherapy plus chemotherapy the new first line standard of care for patients in the recurrent/metastatic setting? Is adjuvant therapy with capecitabine in high risk NPC patients post chemoradiation (CRT) beneficial? Is there a role for treatment intensification by adjuvant metronomic capecitabine in NPC patients post induction chemotherapy and CRT? This article summarizes the most significant NPC studies presented at the ASCO 2021 virtual meeting and discusses the data in the context of the current literature.

scholarly journals Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer

2017 ◽  
Vol 06 (02) ◽  
pp. 064-068
Author(s):  
Lekha Madhavan Nair ◽  
R. Rejnish Kumar ◽  
Kainickal Cessal Thomachan ◽  
Malu Rafi ◽  
Preethi Sara George ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Standard Of Care ◽  
Rank Test ◽  
Advanced Head ◽  
Clinical Trial Registry ◽  
Weekly Cisplatin

Abstract Background: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m2) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent cisplatin regimens. Objectives: The objective of this study was to compare the efficacy and toxicities of 3 weekly cisplatin (100 mg/m2) with weekly cisplatin (40 mg/m2) concurrently with radiation in patients with locally advanced head and neck cancer. Patients and Methods: This phase IIb trial randomized 56 patients with Stage III and IV squamous cell carcinoma of oropharynx, hypopharynx, and larynx to Arm A or Arm B. Arm A received cisplatin 100 mg/m2 3 weekly and Arm B received cisplatin 40 mg/m2 weekly concurrently with radiation. The primary end point was disease-free survival (DFS) and secondary end points were overall survival (OS) and acute toxicity. DFS and OS were estimated using Kaplan–Meier method, and log-rank test was used to assess the difference in these distributions with respect to treatment. Results: The 2-year DFS in Arm A and Arm B was 64.5% and 52.8%, respectively (P = 0.67). The OS at 2 years was 71% and 61.1% in Arm A and Arm B, respectively (P = 0.61). There were no significant differences in acute hematological, renal, or mucosal toxicities between the two arms. Conclusion: This study showed a nonsignificant improvement in DFS and OS in the 3 weekly cisplatin arm over the weekly arm with comparable toxicities. The trial is registered with Clinical Trial Registry of India (CTRI registration number: CTRI/2013/05/003703, URL-http://ctri.nic.in).

scholarly journals Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review

2021 ◽  
Vol 11 ◽  
Author(s):  
Caressa Hui ◽  
Brittney Chau ◽  
Greg Gan ◽  
William Stokes ◽  
Sana D. Karam ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Checkpoint Inhibitors ◽  
Combined Therapy ◽  
Critical Role ◽  
Locally Advanced ◽  
Dose Fractionation ◽  
Metastatic Setting

Radiation therapy remains at the center of head and neck cancer treatment. With improvements in treatment delivery, radiation therapy has become an affective ablative modality for head and neck cancers. Immune checkpoint inhibitors are now also playing a more active role both in the locally advanced and metastatic setting. With improved systemic options, local noninvasive modalities including radiation therapy are playing a critical role in overcoming resistance in head and neck cancer. The aim of this review is to describe the role of radiation therapy in modulating the tumor microenvironment and how radiation dose, fractionation and treatment field can impact the immune system and potentially effect outcomes when combined with immunotherapy. The review will encompass several common scenarios where radiation is used to improve outcomes and overcome potential resistance that may develop with immunotherapy in head and neck squamous cell carcinoma (HNSCC), including upfront locally advanced disease receiving definitive radiation and recurrent disease undergoing re-irradiation. Lastly, we will review the potential toxicities of combined therapy and future directions of their role in the management of HNSCC.

Sign in / Sign up

Export Citation Format

Share Document